Back to Screener

GH Research PLC - Ordinary Shares (GHRS)

NASDAQ Small Cap

Healthcare › Pharmaceutical Preparations

$23.99
Market Cap: $1.5B
Data as of Dec 31, 2025

Price History

Feb 9, 2026 — Jul 6, 2026

Investment Snapshot

  • P/B of 5.32 — trading above book value
  • Piotroski F-Score 4/9 — moderate financial health
  • Loss-making — negative ROE of -17.3%

GH Research PLC - Ordinary Shares (GHRS) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $1.5 billion . Key value metrics: P/B ratio 5.32, Piotroski F-Score 4 out of 9 (moderate financial health) .

Value Score

Key Metrics

P/E Ratio
5.32
EPS
$-0.78
Div. Yield
PEG Ratio
P/S Ratio
EV/EBITDA
ROE
ROA
Gross Margin
Op. Margin
Net Margin
Debt/Equity
Current Ratio
Data sourced from SEC EDGAR and Polygon.io. Methodology. View more Healthcare stocks →

GH Research PLC - Ordinary Shares — Fundamental Analysis Summary

On financial health, GHRS shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -17.3% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.00.

StockPik's composite Value Score for GHRS is 40/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

GHRS shows earnings declining at 24%.

Top Value Stocks in Healthcare

Symbol Price P/E Score
HCM $11.45 4.4 100
CGEN $2.28 6.1 100
GMAB $26.33 1.8 100
BDTX $1.84 3.7 100
EMBC $3.29 1.8 100
How is the Value Score calculated?
Read our full methodology →
What is the Piotroski F-Score?
The 9-point financial health score explained, with worked examples →
Previous
GHM
Next
GIC